What it is
Testagen is KEDG — lysine, glutamic acid, aspartic acid, glycine. Four amino acids, no modifications.
It belongs to the family of short "bioregulator" peptides developed by Vladimir Khavinson's group at the St Petersburg Institute of Bioregulation and Gerontology. Each was proposed to act on one organ, and each was given a name to match: epitalon for the pineal gland, the cartilage peptide Cartalax, pinealon for the brain. Testagen's name points to the testis.
Set KEDG beside epitalon's AEDG and the relationship is plain: the last three residues are identical. Only the first changes.
What the name promises and what the papers test
Sellers offer Testagen as support for the male reproductive system. The question this entry asks is the one a reader should ask of every bioregulator: what was actually measured?
PubMed, searched on 2026-10-28 for "testagen", "Lys-Glu-Asp-Gly" or "KEDG", returns 13 records. Three are false hits — a 1980 sea-slug neuropeptide paper, a 1984 bacterial-protein paper and a 2002 enzyme paper, which contain the letters KEDG inside larger sequences. That leaves ten about this peptide:
| Years | What was studied | In what |
|---|---|---|
| 2008–2013 (5 papers) | Thyroid hormone activity and structure; thymus structure | Young and old chickens with the pituitary surgically removed |
| 2011, 2013 | Entry into the cell nucleus; binding to DNA fragments and plant histones | HeLa cells; test-tube binding |
| 2020 | Review of peptide regulation of cell differentiation | Khavinson group review |
| 2023 | Whether 26 short peptides fit amino-acid transporters | Computer docking only |
| 2025 | Peptide adsorbing to copper in salt water | Corrosion chemistry |
None of the ten studies testis tissue, sperm, testosterone or fertility. Several of the bird papers describe KEDG as a pituitary ("hypophyseal") peptide, which is how it was framed in its own literature; the testis framing appears on sales pages, not in the indexed research.
That gap is the most useful fact about Testagen, and it is checkable: the PubMed search string is in this entry's facts.
The human record
There is none. ClinicalTrials.gov has a single result for "Testagen" — NCT02733133, a product-transference study of Testagen TDS, a testosterone skin product that shares the trademark. It has nothing to do with the peptide, and it is easy to mistake for evidence if only the name is searched.
Who produced the evidence
As with epitalon and Thymalin, the biological papers come from one programme and its collaborators. That is how research on a new compound often starts. It means the record has not yet been tested by laboratories with no stake in it, and — in Testagen's case — that even the originating group's published work does not address the use the product is sold for.
Where it stands
Approved as a medicine: nowhere.
Human evidence: none published.
Animal and cell evidence: ten papers, 2008–2025, mostly thyroid and thymus effects in hypophysectomised chickens.
Questions about testosterone, fertility or symptoms that prompted the search belong with a doctor who can order the relevant tests; this entry reports what the published record contains.
Last checked
2026-10-28.